Trofosfamide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Trofosfamide
DrugBank Accession Number
DB12902
Background

Trofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 323.58
Monoisotopic: 322.0171479
Chemical Formula
C9H18Cl3N2O2P
Synonyms
  • Trofosfamide

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hover over products below to view reaction partners

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Trofosfamide.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Trofosfamide.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Trofosfamide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Trofosfamide.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Trofosfamide.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trofosfamide.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Trofosfamide.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Trofosfamide.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Trofosfamide.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trofosfamide.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
L01AA07 — Trofosfamide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as isofamides. These are oxazaphospholanes containing the isofamide skeleton. Isofamide is a heterocyclic compound made up of a 1,3,2-oxazaphospholane, where the phosphorus atom is part of a phosphodiamide group, and the oxazaphospholane is substituted by two haloalkyl chains.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazaphosphinanes
Sub Class
Isofamides
Direct Parent
Isofamides
Alternative Parents
Nitrogen mustard compounds / Phosphoric monoester diamides / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Alkyl chlorides
Substituents
Aliphatic heteromonocyclic compound / Alkyl chloride / Alkyl halide / Azacycle / Hydrocarbon derivative / Isofamide / Nitrogen mustard / Organic nitrogen compound / Organic oxide / Organic oxygen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
H64JRU6GJ0
CAS number
22089-22-1
InChI Key
UMKFEPPTGMDVMI-UHFFFAOYSA-N
InChI
InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
IUPAC Name
2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)-1,3,2lambda5-oxazaphosphinan-2-one
SMILES
ClCCN(CCCl)P1(=O)OCCCN1CCCl

References

General References
Not Available
PubChem Compound
65702
PubChem Substance
347829054
ChemSpider
59129
RxNav
38865
ChEBI
135381
ChEMBL
CHEMBL462019
Wikipedia
Trofosfamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2, 3CompletedTreatmentEpendymomas / Medulloblastomas / Recurrent Brain Tumors / Supratentorial PNETs1
1, 2Unknown StatusTreatmentAdvanced Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.0 mg/mLALOGPS
logP1.4ALOGPS
logP0.98ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)0.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity72.72 m3·mol-1ChemAxon
Polarizability29.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 21, 2016 01:08 / Updated on February 21, 2021 18:54